患者对转移性黑色素瘤治疗的偏好。

Patient preferences for treatment of metastatic melanoma.

机构信息

RTI Health Solutions, Research Triangle Park, NC 27709, USA.

Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.

出版信息

Future Oncol. 2019 Apr;15(11):1255-1268. doi: 10.2217/fon-2018-0871. Epub 2019 Jan 29.

DOI:10.2217/fon-2018-0871

PMID:30694080

Abstract

AIM

To investigate patient preferences for clinical attributes of first-line metastatic melanoma treatments.

MATERIALS & METHODS: A discrete-choice experiment and best-worst scaling exercise were used to assess relative preferences for treatment attributes.

RESULTS

The 200 survey respondents had distinct preferences. Avoiding a 30% risk of colitis or hormone gland problems and avoiding severe fever were more important to respondents than avoiding a 20% risk of extreme sun sensitivity (p < 0.05). Patients preferred taking pills to receiving intravenous infusions in a clinic. When attributes were combined, approximately 85% of respondents preferred a risk profile similar to targeted therapy over a profile similar to immunotherapy, holding efficacy constant.

CONCLUSION

Taking patient preferences into account can help patients get the full benefit from metastatic melanoma therapies.

摘要

目的

调查患者对一线转移性黑色素瘤治疗方案临床特征的偏好。

材料与方法

采用离散选择实验和最佳最差标度法评估治疗特征的相对偏好。

结果

200 名调查对象具有明显的偏好。避免 30%结肠炎或激素腺体问题风险和避免严重发热对患者比避免 20%极端阳光敏感风险更为重要（p<0.05）。患者更喜欢服用药丸，而不是在诊所接受静脉输液。当综合考虑这些属性时，在保持疗效不变的情况下，大约 85%的受访者更倾向于靶向治疗的风险状况，而不是免疫治疗。